Table 3.

Pregnancy outcomes by study arm and cohort

Cohort 1	Dapivirine arm (n=99)* n (%)	TDF/FTC arm (n=49) n (%)	Both arms (n=148) n (%)
Live births	99 (100)	48 (98)	147 (99)
Full term (≥ 37weeks)	98 (99)	46 (96)	144 (98)
Premature (<37 weeks)	1 (1)	2 (4)	3 (2)
Stillbirth/intrauterine fetal demise	0 (0)	1 (2)	1 (1)
Cohort 2	Dapivirine arm (n=104)* n (%)	TDF/FTC arm (n=50) n (%)	Both arms (n=154) n (%)
Live births	103 (99)	51 (100)**	154 (99)
Full term (≥ 37weeks)	97 (94)	47 (92)	144 (94)
Premature (<37 weeks)	6 (6)	4 (8)	10 (6)
Stillbirth/intrauterine fetal demise	1 (1)	0 (0)	1 (1)

^*Number of participants with obtainable pregnancy outcomes

Abbreviations: TDF/FTC= tenofovir disoproxil fumarate/emtricitabine

^**51 live births amongs 50 women as one woman had undiagnosed twins